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Genetics of epilepsy
The testimony of twins in the molecular era
ABSTRACT
Objective: Analysis of twins with epilepsy to explore the genetic architecture of specific epilep-
sies, to evaluate the applicability of the 2010 International League Against Epilepsy (ILAE) orga-
nization of epilepsy syndromes, and to integrate molecular genetics with phenotypic analyses.
Methods: A total of 558 twin pairs suspected to have epilepsy were ascertained from twin regis-
tries (69%) or referral (31%). Casewise concordance estimates were calculated for epilepsy syn-
dromes. Epilepsies were then grouped according to the 2010 ILAE organizational scheme.
Molecular genetic information was utilized where applicable.
Results: Of 558 twin pairs, 418 had confirmed seizures. A total of 534 twin individuals were
affected. There were higher twin concordance estimates for monozygotic (MZ) than for dizygotic
(DZ) twins for idiopathic generalized epilepsies (MZ 5 0.77; DZ 5 0.35), genetic epilepsy with
febrile seizures plus (MZ 5 0.85; DZ 5 0.25), and focal epilepsies (MZ 5 0.40; DZ 5 0.03).
Utilizing the 2010 ILAE scheme, the twin data clearly demonstrated genetic influences in the
syndromes designated as genetic. Of the 384 tested twin individuals, 10.9% had mutations of
large effect in known epilepsy genes or carried validated susceptibility alleles.
Conclusions: Twin studies confirm clear genetic influences for specific epilepsies. Analysis of the
twin sample using the 2010 ILAE scheme strongly supported the validity of grouping the
“genetic” syndromes together and shows this organizational scheme to be a more flexible and
biologically meaningful system than previous classifications. Successful selected molecular test-
ing applied to this cohort is the prelude to future large-scale next-generation sequencing of epi-
lepsy research cohorts. Insights into genetic architecture provided by twin studies provide
essential data for optimizing such approaches. Neurology® 2014;83:1042–1048
GLOSSARY
BECTS5 benign epilepsywith centrotemporal spikes;CAE5 childhood absence epilepsy;DS5Dravet syndrome;DZ5 dizygotic;
FE5 focal epilepsies; FS5 febrile seizures; FS15 febrile seizures plus;GE5 generalized epilepsies;GEFS15 genetic epilepsy
with febrile seizures plus; IFE 5 idiopathic focal epilepsies; IGE 5 idiopathic generalized epilepsies; ILAE 5 International League
Against Epilepsy; IPOE 5 idiopathic photosensitivity occipital epilepsy; JME 5 juvenile myoclonic epilepsy; MAS 5 epilepsy with
myoclonic-atonic seizures;MZ5monozygotic;SGE5 symptomatic generalized epilepsies; SSCP5 single-stranded conformation
polymorphism; TLE 5 temporal lobe epilepsy.
William Lennox,1 a pioneering epileptologist, realized the value of twin studies in genetics,
highlighting “the testimony of twins” in his monumental 1960 book.2 His work predated formal
classification systems and his cohort was clinically ascertained. Later population-based twin
studies minimized ascertainment bias, but lacked precision in syndrome diagnoses.3–7 Subse-
quent twin research utilizing the 1989 International League Against Epilepsy (ILAE) classifi-
cation system8 incorporating both syndromic analyses and population samples showed clear
genetic influences for generalized epilepsies (GE), febrile seizures (FS), and even for focal epi-
lepsies (FE).9,10 Indeed, reanalysis of Lennox’s original data largely confirmed strong genetic
influences for broad epilepsy syndromes.11
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To incorporate major neuroscientific advan-
ces in understanding human epilepsies, the
ILAE developed revised terminology and con-
cepts for organization of seizures and epilepsies
in 2010.12 This framework, which is not yet a
formal scientific classification, provides flexible
concepts that better reflect our current under-
standing of epilepsies,12 especially in genetics.13
Channelopathies are a major known mecha-
nism in idiopathic epilepsies,14–16 but non-ion
channel genes such as LGI1,17 SLC2A1,18,19
and DEPDC520 are also important causes of
Mendelian epilepsies. Susceptibility alleles are
much more challenging to confirm, but some,
such as variants inCACNA1H and the 15q13.3
microdeletion, are established.21,22
We analyze the genetic influences for specific
epilepsy syndromes with a large twin cohort,
incorporating advances in syndromic diagnoses.
Next, we review the utility of the 2010 ILAE
organizational scheme.12 Finally, we analyze
the yield of selected molecular genetic testing
applied to this cohort.
METHODS Ascertainment of twins and clinical
assessment. Twins were ascertained since 1988 from multiple
twin registries or by referral; all cases were Australian. The clinical
methodology as detailed in our earlier report comprised clinical
assessment, rigorous record review, EEG, and follow-up.10 If
the diagnostic evaluation excluded true epileptic seizures, the twin
individual was labeled as false-positive. If a twin had an EEG
abnormality, but no history of seizures, he or she was classified
as unaffected.
Our earlier study reported 358 pairs with definite or sus-
pected seizures10; here we increased the cohort to 558 pairs. Twin
diagnoses have been updated since initial ascertainment due to
follow-up data and evolving diagnoses. All early twin pairs were
re-reviewed as new syndromes such as genetic epilepsies with FS
plus (GEFS1) were introduced and others such as Dravet syn-
drome (DS) were better recognized.
In the early cohort, analyses of red cell antigens and human
leukocyte antigen markers were performed to confirm zygosity,
whereas in the later cohort at least 9 different polymorphic
DNA markers were assayed. If all markers were concordant, the
twin pairs were designated monozygotic (MZ). In cases where
the laboratory zygosity was not performed, zygosity was deter-
mined on clinical findings and a zygosity questionnaire, which
has greater than 95% accuracy.23
Standard protocol approvals, registrations, and patient
consents. The Human Research Ethics Committee of Austin
Health approved the protocol. Written informed consent was
obtained from all patients or their guardians.
1989 ILAE classification of epilepsies. The general frame-
work was based on the ILAE classification of epilepsies and epileptic
syndromes, as previously described.8 Briefly, twin individuals were
divided into 5 broad epilepsy groups, which consisted of GE, FE,
FS alone, special syndromes, and unclassified epilepsies. Twin
individuals could be classified into more than one broad epilepsy
group. FS were included in their own broad group to enable sep-
arate analyses.
The broad epilepsy groups were then divided using the 1989
ILAE classification.8 GE were divided into idiopathic GE (IGE),
GEFS1 spectrum, symptomatic GE (SGE), and unclassified GE.
IGE included childhood absence epilepsy (CAE), juvenile absence
epilepsy, and juvenile myoclonic epilepsy (JME). The GEFS1
spectrum included a range of phenotypes including FS plus
(FS1), epilepsy with myoclonic-atonic seizures (MAS), and DS.24
FE were divided into idiopathic FE (IFE), idiopathic photo-
sensitivity occipital epilepsy (IPOE), symptomatic FE, and
unclassified FE. For temporal lobe epilepsy (TLE), because of
emerging evidence of a major genetic component in cases without
lesions,25 we also used a specific category of nonlesional TLEs as
these fall under the 1989 definition of IFE. We included cases
with clinical or electrographic support for temporal lobe seizure
origin, without structural abnormalities on MRI.
2010 ILAE organization of the epilepsies. In this scheme,
the underlying cause was categorized into 3 groups—genetic,
structural/metabolic, and unknown.12 Genetic presumes the epi-
lepsy syndrome is a direct cause of a known or presumed genetic
defect, where seizures are the main symptom of the disorder.12
Structural/metabolic causes are where these distinct causes were
associated with an increased risk of epilepsies. Even if the struc-
tural cause may also be due to a genetic defect, there is a separate
disorder interposed between the genetic defect and epilepsy.12
Terminology from the old classification system such as symp-
tomatic and cryptogenic was no longer in the new organization;
hence these cases were reclassified using the new terminology.
The original symptomatic focal group was reviewed and divided
into lesional TLEs and other lesional FE. Lesional was defined
by the presence of a structural abnormality on MRI. Cryptogenic
FE were generally designated as nonlesional TLEs (see above) and
other FE.
The original SGE group was also reviewed and divided into
malformations of cortical development, progressive myoclonic
epilepsies, and others (including epilepsy of infancy with migrat-
ing focal seizures and unclassified).
The neonatal seizure group from the old classification was re-
viewed and divided into benign neonatal seizures and other epi-
lepsies with neonatal seizures (incorporating those associated
with other seizure disorders or unclassified).
Molecular testing. Molecular testing was not carried out for the
whole cohort. Twin individuals were tested when they had syn-
dromes suspected to be associated with variation in specific genes.
Twin individuals who were tested and had genomic variants for
either genes of large effect or susceptibility alleles for the few known
genes for epilepsies with complex inheritance were studied further
for concordance or nonconcordance of epilepsy phenotype.
Patients were screened for mutations in SCN1A by denatur-
ing high-performance liquid chromatography and for mutations
or variants in other genes by single-stranded conformation poly-
morphism (SSCP) analysis. Sequence variants detected by either
screening method were analyzed by direct Sanger sequencing.
Statistical methods. Casewise concordance, defined as the
probability that one member of a twin pair is affected given that
the other is affected, was estimated as Pc5 2nc/(2nc1 nd), where
nc is the number of concordant pairs and nd the number of dis-
cordant pairs. Under the assumption of complete ascertainment
of seizure status, this is an unbiased estimator with asymptotic
standard error O[Pc (12Pc) (22Pc)/(2nc 1 nd)].26 The hypoth-
eses that concordance was independent of zygosity, and disease
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subtype, were tested using the likelihood ratio criterion. That is, the
log-likelihood for a model estimating a single concordance for all
twin pairs pooled was subtracted from the sum of the log-likelihoods
for a model estimating concordance separately for MZ and dizygotic
(DZ) pairs and this statistic was compared to a x2 distribution with
1 degree of freedom. All quoted p values were 2-sided.
In those twin individuals classified as having more than one
broad epilepsy group diagnosis, concordances were estimated
for each broad group. In the cases where FS or special syndromes
occurred in association with epilepsy syndromes (generalized,
focal, or unclassified epilepsies), they were classified by concor-
dance for the epilepsy syndrome only.
Where twin pairs were concordant for a broad syndrome, but
discordant for a specific syndrome, they were counted once (as
discordant) in the specific syndrome analysis, with only the pro-
band’s syndrome listed.
RESULTS Cohort characteristics. There were a total of
1,116 twin individuals (558 twin pairs) in the cohort.
Ascertainment of twins was predominantly from twin
registries (69%) with direct referral accounting for
31%. There were 651 female (53%) and 465 male
(47%) participants. There were 6 triplet sets in the
database; these were analyzed as single pairs in order
not to inflate their effect on the analysis. In 5 of the
triplet sets, only 1 was affected, hence 1 unaffected
triplet was excluded to enable the set to be counted
as a single discordant “twin” pair. In the final set,
all 3 had IGE and were counted as a single concor-
dant pair.
There were 158 twin individuals who were deemed
as false-positive for epilepsies. Although they self-
reported seizures or suspected seizures, after clinical
review other diagnoses were made. The false-positive
diagnoses were syncope (n5 44), breath-holding (n5
29), behavioral events (n 5 13), febrile syncope (n 5
10), movement disorders (n5 5), night terrors (n5 3),
reflux (n 5 3), migraine (n 5 2), and uncertain (n 5
49). The 158 false-positive twin individuals were part
of 140 twin pairs classified as false-positives, as some
twin pairs were concordant for false-positive diagno-
ses. After excluding these 140 false-positive twin pairs,
there were 418 twin pairs for analysis.
Table 1 shows zygosity and seizure concordance in
418 twin pairs, including 534 affected twin individuals.
1989 ILAE classification of epilepsies. The 534 twin
individuals were classified into the broad epilepsy
groups of GE, FE, FS, special syndromes, and
unclassified epilepsies. If twin individuals were clas-
sified with more than one broad group, concordan-
ces were determined for each broad group, leading
to a total of 457 diagnostic comparisons from the
418 twin pairs.
Casewise concordances for seizures and broad epilepsy
groups. Table 2 shows the casewise concordance esti-
mates for all seizures and broad epilepsy groups. The
estimated MZ casewise concordances were signifi-
cantly different from the estimated DZ casewise con-
cordances for the occurrence of seizures as a whole, as
well as the broad epilepsy groups of generalized, focal,
and febrile seizures. The estimated MZ casewise con-
cordance for GE was higher than that for FE (0.79 vs
0.40, p , 0.0001). Similarly, the estimated DZ case-
wise concordance was higher for GE compared with
FE (0.29 vs 0.03, p 5 0.002).
Casewise concordances for specific syndromes. Table 3
shows that all GE syndromes had higher MZ casewise
concordance estimates compared with DZ casewise
concordance estimates. As previously reported,27 in
the FE, there was striking MZ and DZ discordance
for benign epilepsy with centrotemporal spikes
(BECTS) (MZ 5 0; DZ 5 0), despite long being
regarded as an idiopathic epilepsy with a presumed
genetic basis. The nonlesional temporal lobe group
Table 1 Overview of the 418 twin pairs with
confirmed seizures
No. of twin pairs MZ DZ
Zygosity (418) 194a 224a
Seizure concordant pairs (116) 92 24
Seizure discordant pairs (302) 102 200
Broad group concordances (457)b 217 240
Abbreviations: DZ 5 dizygotic; MZ 5 monozygotic.
a Includes 15 MZ pairs and 22 same-sex DZ pairs where
zygosity was determined on clinical grounds alone.
b In those twin individuals classified as having more than
one broad epilepsy group diagnosis, concordances were
estimated for each broad group.
Table 2 Casewise concordance estimates for seizures and broad epilepsy
groups using 1989 ILAE classification
Seizures and broad epilepsy
groups (no. of MZ twin
pairs, no. of DZ twin pairs)
Casewise
concordance
p ValueaMZ DZ
All seizures (194, 224) 0.64 0.19 ,0.0001
Broad groupsb (217, 240)
Generalized epilepsies (63, 60) 0.79 0.29 ,0.0001
Focal epilepsies (60, 60) 0.40 0.03 ,0.0001
Febrile seizures alone (48, 80) 0.59 0.10 ,0.0001
Special syndromes
Neonatal seizures (10, 16) 0.46 0 0.01
Othersc (10, 9) 0 0 —
Unclassified epilepsies (25, 15) 0.39 0.24 0.4
Abbreviations: DZ 5 dizygotic; ILAE 5 International League Against Epilepsy; MZ 5
monozygotic.
a Analysis of difference in concordance between MZ and DZ twin pairs.
b In those twin individuals classified as having more than one broad epilepsy group,
diagnosis concordances were estimated for each broad group.
cOthers in the special syndrome group included single seizures, acute symptomatic
seizures, and epilepsy-aphasia syndromes.
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showed higher MZ casewise concordance com-
pared with DZ casewise concordance (MZ 5 0.82;
DZ 5 0; p 5 0.003).
GEFS1 spectrum. The GEFS1 spectrum was recog-
nized after initiation of the twin study and reanalysis
provides new insights. First, concordance estimates
(MZ 5 0.85; DZ 5 0.25; p 5 0.0009) provide
strong evidence of a major genetic effect. Second,
among the 15 concordant MZ twin pairs with the
GEFS1 spectrum, there was no further family history
of seizures in 7 of the twin pairs. Only one MZ twin
pair had more than 4 family members affected (ascer-
tained by referral as a multiplex family). In the 14 DZ
twin pairs with the GEFS1 spectrum, there was no
other family history in 4 of the DZ twin pairs. There
were 4 DZ twin pairs with greater than 4 affected and
notably all these families were ascertained by referral.
2010 ILAE organization. Table 4 shows casewise concor-
dances estimates for epilepsies divided into the 3 etiologic
groups: genetic, structural/metabolic, and unknown.
Casewise concordances for genetic causes. As expected,
there were higher MZ casewise concordance estimates
compared with DZ casewise concordance estimates in
the epilepsies deemed genetic in the 2010 scheme. In
particular, the estimated MZ casewise concordances
were higher than the estimated DZ casewise concor-
dance in CAE, JME, FS1, MAS, FS alone, and
benign neonatal seizures. In DS, there was a high
MZ concordance estimate, but as there were no DZ
twin pairs, a p value could not be calculated.
Casewise concordances for structural/metabolic causes.
In the lesional TLEs group and acute symptomatic
seizures, there were no concordant MZ pairs, sup-
porting a nongenetic basis to these epilepsies. The
group with malformations of cortical development
showed a trend toward higher concordances in MZ
twin pairs compared with DZ twin pairs, but the
sample size was small.
Casewise concordances for unknown causes. High MZ
concordance was seen in the IPOE and nonlesional
TLE group. No MZ concordance was seen in the neo-
natal seizure group, BECTS, or benign occipital epilepsy.
Molecular analysis. Molecular testing in twins was not
systematic and was performed over a 15-year period
in those twin individuals with symptoms or family
history suggestive of syndromes with known genes.
There were 384 twin individuals tested out of the
534 twin individuals with seizures and gene variants
were detected in 37 twin individuals, with a total of
42 variants found as some twin individuals had more
than one detected gene variant. Mutations of large
effect were found in 4.4% of twin individuals (n 5
17) and susceptibility variants in the few known sus-
ceptibility genes were found in 6.5% of twin individ-
uals (n 5 25). The most common gene in which
variation was detected was SCN1A, as 10/55 (18%)
twin individuals were found to have this pathogenic
mutation. Table e-1 on the Neurology® Web site at
Neurology.org integrates the molecular findings with
epilepsy syndromes.
DISCUSSION This twin analysis incorporates advan-
ces in syndromic diagnoses and molecular analyses on
a larger cohort than previously reported,10 facilitating
clearer interpretation of the genetic influences for spe-
cific epilepsy syndromes and in particular the syn-
dromic groups of IGE and GEFS1 spectrum.
Using the 1989 ILAE Classification, we confirm
previous twin studies, showing there are clear genetic
influences in GE, FE, and FS, as well as greater concor-
dances in MZ twin pairs for GE compared with FE.9,10
Table 3 Casewise concordance estimates for specific epilepsy syndromesa
Syndromes (no. of MZ twin pairs, no.
of DZ twin pairs)
Casewise concordance
p ValuebMZ DZ
Generalized (63, 60) 0.79 0.29 ,0.0001
Idiopathic generalized epilepsies
(38, 38)
0.77 0.35 0.0002
Genetic epilepsies with febrile
seizures plus spectrum (15, 14)
0.85 0.25 0.0009
Febrile seizures plus (8, 8) 0.86 0 0.0005
Epilepsy with myoclonic-atonic
seizures (4, 5)
0.86 0 0.008
Dravet syndrome (3, 1) 0.80 0 0.2
Symptomatic generalized
epilepsies (7, 5)
0.73 0 0.02
Unclassified generalized
epilepsies (3, 3)
0.80 0 0.05
Focal (60, 60) 0.40 0.03 ,0.0001
Idiopathic focal epilepsies (7, 11) 0 0.17 0.3
Benign epilepsy with
centrotemporal spikes (6, 6)
0 0 —
Benign occipital epilepsies (1, 5) 0 0.33 0.5
Nonlesional temporal lobe
epilepsyc (13, 5)
0.82 0 0.003
Idiopathic photosensitivity
occipital epilepsy (4, 0)
0.86 — —
Othersd (3, 0) 0.80 — —
Symptomatic focal epilepsies
(24, 28)
0.08e 0 0.2
Unclassified focal epilepsies
(9, 16)
0 0 —
Abbreviations: DZ 5 dizygotic; MZ 5 monozygotic.
a This table does not include the broad groups of febrile seizures alone, special syndromes,
and unclassified epilepsies.
bAnalysis of difference in concordance between MZ and DZ twin pairs.
c Nonlesional temporal lobe epilepsies were defined as those with clinical or electrographic
support for temporal lobe seizure origin, without structural abnormality on MRI.
d Includes frontal lobe epilepsies, autosomal dominant rolandic epilepsy with speech
dyspraxia, and reading epilepsies.
e The single concordant MZ twin pair had periventricular nodular heterotopia.
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Particularly important is the clear genetic influ-
ence in FE, especially when divided into specific syn-
dromes. BECTS has long been assumed to be largely
genetic in origin, but the twin data did not support
this, with no MZ concordance in our study. Our
analysis of the BECTS twins previously highlighted
that the etiology and genetics of BECTS is more com-
plicated than initially conceptualized.27,28 The twin
data support genetic influences in nonlesional TLEs;
within this grouping, familial TLE is the most impor-
tant.29,30 A combination of twin and family data sup-
ports complex inheritance for most cases,25 although
there is the well-recognized exception of autosomal
dominant FE with auditory features, often due to
mutations in LGI1,17,31 which was not identified in
our twins.
GEFS1 was not described at the time of the 1989
classification. Previous research defining the GEFS1
spectrum was based on rare large multiplex fami-
lies.32,33 Whereas these rare families demonstrate auto-
somal dominant inheritance, the marked phenotypic
heterogeneity within and between families supports a
more complex etiology.33 The twin analysis confirms
clear genetic influences for the GEFS1 spectrum, with
very high MZ concordance estimates. However,
important additional insights have been gained from
the family histories of the twins, as additional affected
family members were usually not found. Thus, while
the twin data confirm that there is clearly a genetic
influence in GEFS1, the actual inheritance pattern
is usually complex, with the initially described large
autosomal dominant families being the exception.
Multiple genes of small effect, possibly in combination
with environmental influences, stochastic factors, or
epigenetic modifications, may all play a role in
GEFS1. The clinical genetics of FS and their relation-
ship to GEFS1 in this twin sample are explored
elsewhere.34
This analysis provided strong direct support for
the value of the new 2010 ILAE organizational sys-
tem. Notably, for syndromes deemed genetic, the
twin data uniformly demonstrated high MZ concor-
dance estimates (table 4), supporting the premise that
these epilepsies have strong genetic influences.12 Con-
versely, for the structural/metabolic group, the data
supported nongenetic influences in the majority, with
the exception of certain malformations and progress-
ive myoclonic epilepsies that are known to have a
genetic basis, but according to the new classification,
“there is a separate disorder interposed between the
genetic defect and the epilepsies.”12 The new classifi-
cation facilitates a mechanism of separating syn-
dromes for which genetic influences may either
directly or indirectly cause epilepsies.
In the unknown causes group, the twin data pre-
sented a mixed picture, with genetic influences in
some epilepsies and no genetic influences in others.
This mixed group highlighted the potential flexibility
of this system in an era of evolving understanding of
the pathophysiology of epilepsies. For instance, for
Table 4 Casewise concordance estimates for epilepsies using 2010 ILAE
organization for specific syndromes (354 twin pairsa)
Syndromes (no. of MZ twin pairs, no.
of DZ twin pairs)
Casewise
concordance
p ValuebMZ DZ
Genetic causes
Childhood absence epilepsy
(16, 17)
0.86 0.22 0.0002
Juvenile absence epilepsy (8, 4) 0.50 0 0.10
Juvenile myoclonic epilepsy (6, 9) 0.91 0 0.0002
Febrile seizures plus (8, 8) 0.86 0 0.0005
Epilepsy with myoclonic-atonic
seizures (4, 5)
0.86 0 0.008
Dravet syndrome (3, 1) 0.80 0 0.2
Febrile seizures alone (48, 80) 0.59 0.10 ,0.0001
Benign neonatal seizures (4, 2) 0.86 0 0.05
Autosomal dominant rolandic
epilepsy with speech dyspraxia
(1, 0)
1.0 0 —
Structural/metabolic causes
Lesional temporal lobe epilepsies
(7, 11)
0 0 —
Other focal lesional epilepsies
(8, 15)c
0 0 —
Acute seizure due to a known
cause (6, 7)
0 0 —
Malformations of cortical
development (3, 2)
0.5 0 0.3
Neurofibromatosis 1 (2, 0) 0 — —
Progressive myoclonic epilepsies
(2, 0)
1.0 0 —
Unknown causes
Other epilepsies with neonatal
seizures (6, 14)d
0 0 —
Idiopathic photosensitive
occipital epilepsies (4, 0)
0.86 — —
Benign epilepsy with
centrotemporal spikes (6, 6)
0 0 —
Benign occipital epilepsies (1, 5) 0 0.33 0.5
Nonlesional temporal lobe
epilepsies (13, 5)
0.82 0 0.003
Other focal epilepsies (5, 2) 0 0 —
Abbreviations: DZ 5 dizygotic; ILAE 5 International League Against Epilepsy; MZ 5
monozygotic.
a This table does not include the following groups (64 twin pairs): unclassified epilepsies (40
twin pairs); others in the special syndrome group—single seizures (3 twin pairs), epilepsy-
aphasia syndrome (3 twin pairs); others in the partial group—frontal epilepsy (1 twin pair),
reading epilepsy (1 twin pair); others in the generalized group (16 twin pairs)—generalized
tonic-clonic seizures alone, idiopathic generalized epilepsy unspecified, benign myoclonic
epilepsy, late-onset idiopathic epilepsy.
bAnalysis of difference in concordance between MZ and DZ twin pairs.
c Includes frontal, occipital, mixed, and unclassified.
d Includes neonatal seizures in association with other epilepsies and unclassified cases.
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familial TLEs, our evolving understanding of the
genetic influences based on twin and family data25,29,30
suggests that this group would be better placed in the
genetic group. Similarly, our evolving understanding of
IPOE supports a genetic basis for this disorder.35
Understanding etiology and communicating to pa-
tients and families is an essential part of counseling
and, in the case of epilepsies with a genetic etiology,
this can be done in the clinic, even if specific genes are
not known or identified.
The study highlighted the potential role of the
new etiologically based system and in particular its
flexibility for the evolving understanding of the epi-
lepsies. The molecular data complement the clinical
twin studies and show an appreciable diagnostic yield
in this largely community-acquired cohort, even
using older, single gene–directed technologies. The
most frequent gene in which mutations were identi-
fied was SCN1A, in keeping with this currently being
the most clinically relevant epilepsy gene.36 We
acknowledge that this testing was incomplete, and
our yield is a minimal estimate, particularly as tech-
niques such as SSCP have an appreciable false-
negative rate with certain genes such as SCN1A.37
These data highlight the potential to integrate well-
established clinical data with molecular genetic find-
ings and pave the way for targeted next-generation
sequencing of large cohorts, which is likely to be the
next phase in diagnosis, treatment guidance, and
genetic counseling.38,39 Moreover, these data extend
our understanding of the genetics and genetic interre-
lationships in the various epilepsy syndromes that is
vital to strategic planning of nontargeted, genome-
wide discovery using next-generation sequencing.
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